lamotrigine has been researched along with Acute Disease in 42 studies
Acute Disease: Disease having a short and relatively severe course.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Topiramate appears to show promise as an addition to the agents available to treat bipolar disorder." | 10.19 | The evolving role of topiramate among other mood stabilizers in the management of bipolar disorder. ( Chengappa, KN; Gershon, S; Levine, J, 2001) |
| " There was no convincing evidence that lamotrigine is effective in treating neuropathic pain and fibromyalgia at doses of 200 mg to 400 mg daily." | 8.89 | Lamotrigine for chronic neuropathic pain and fibromyalgia in adults. ( Derry, S; Moore, RA; Wiffen, PJ, 2013) |
| "RCTs investigating the use of lamotrigine (any dose, by any route, and for any study duration) for the treatment of acute or chronic pain." | 8.87 | Lamotrigine for acute and chronic pain. ( Derry, S; Moore, RA; Wiffen, PJ, 2011) |
| "To assess the analgesic efficacy and adverse effects of the anticonvulsant lamotrigine for acute and chronic pain." | 8.84 | Lamotrigine for acute and chronic pain. ( Rees, J; Wiffen, PJ, 2007) |
| " We evaluated the neuroprotective effects of lamotrigine, a Nav blocker, in the acute and chronic rat ocular hypertension models." | 7.79 | Functional and structural evaluation of lamotrigine treatment in rat models of acute and chronic ocular hypertension. ( Bähr, M; Hein, K; Könnecke, B; Levkovitch-Verbin, H; Ofri, R; Sandalon, S; Sättler, MB; Simons, M, 2013) |
| "Lamotrigine has emerged as a first line treatment for bipolar depression, which is an area of weakness for other mood stabilizers." | 6.42 | Separate and concomitant use of lamotrigine, lithium, and divalproex in bipolar disorders. ( Goodwin, FK; Lieberman, DZ, 2004) |
| "Topiramate appears to show promise as an addition to the agents available to treat bipolar disorder." | 6.19 | The evolving role of topiramate among other mood stabilizers in the management of bipolar disorder. ( Chengappa, KN; Gershon, S; Levine, J, 2001) |
| "Acute interstitial nephritis is a mononuclear and sterile inflammation of the renal interstice caused by drugs, infections or immune phenomena." | 5.32 | [Acute interstitial nephritis associated to lamotrigine use. Report of one case]. ( Mönckeberg, G; Rosenberg, H; Valls, G; Vukusich, A, 2004) |
| "Preliminary data from case reports and small open trials suggest a role for lamotrigine in the treatment of bipolar disorder, although controlled data for the manic phase are lacking." | 5.09 | Lamotrigine compared with lithium in mania: a double-blind randomized controlled trial. ( Berk, M; Brook, S; Ichim, L, 2000) |
| "The 2 older FDA-approved treatments for bipolar depression, olanzapine-fluoxetine combination (OFC) and quetiapine (QTP) monotherapy, were efficacious (response NNT=4 for OFC, NNT=6 for QTP), but similarly likely to yield harms (OFC weight gain NNH=6; QTP sedation/somnolence NNH=5)." | 4.90 | Balancing benefits and harms of treatments for acute bipolar depression. ( Calabrese, JR; Citrome, L; Dell'Osso, B; Frye, MA; Ketter, TA; Miller, S, 2014) |
| " There was no convincing evidence that lamotrigine is effective in treating neuropathic pain and fibromyalgia at doses of 200 mg to 400 mg daily." | 4.89 | Lamotrigine for chronic neuropathic pain and fibromyalgia in adults. ( Derry, S; Moore, RA; Wiffen, PJ, 2013) |
| "RCTs investigating the use of lamotrigine (any dose, by any route, and for any study duration) for the treatment of acute or chronic pain." | 4.87 | Lamotrigine for acute and chronic pain. ( Derry, S; Moore, RA; Wiffen, PJ, 2011) |
| "To assess the analgesic efficacy and adverse effects of the anticonvulsant lamotrigine for acute and chronic pain." | 4.84 | Lamotrigine for acute and chronic pain. ( Rees, J; Wiffen, PJ, 2007) |
| " We evaluated the neuroprotective effects of lamotrigine, a Nav blocker, in the acute and chronic rat ocular hypertension models." | 3.79 | Functional and structural evaluation of lamotrigine treatment in rat models of acute and chronic ocular hypertension. ( Bähr, M; Hein, K; Könnecke, B; Levkovitch-Verbin, H; Ofri, R; Sandalon, S; Sättler, MB; Simons, M, 2013) |
| "The novel anti-epileptic drugs lamotrigine, felbamate and gabapentin were compared in rat experimental models of acute (tail flick) and chronic pain: the chronic constriction injury and spinal nerve ligation models." | 3.69 | The effect of novel anti-epileptic drugs in rat experimental models of acute and chronic pain. ( Fontana, DJ; Gogas, KR; Hedley, LR; Hunter, JC; Jacobson, LO; Kassotakis, L; Thompson, J, 1997) |
| "Lamotrigine and lithium were effective monotherapy for BDII depression, with comparable response and remission rates." | 2.73 | A single blind comparison of lithium and lamotrigine for the treatment of bipolar II depression. ( Al Jurdi, R; Bernstein, IH; Fischer, EG; Gonzalez, R; Kelly, DI; Marangell, LB; Martinez, M; Shivakumar, G; Snow, DE; Suppes, T; Sureddi, S; Zboyan, HA, 2008) |
| "Persistence of invalidating action myoclonus is a major problem." | 2.72 | Lack of efficacy and potential aggravation of myoclonus with lamotrigine in Unverricht-Lundborg disease. ( Crespel, A; Gelisse, P; Genton, P, 2006) |
| "While both unipolar and bipolar depression have serious detrimental effects on patient QOL, our results suggest that some aspects of QOL may be worse in bipolar depression." | 2.71 | Quality of life in patients with bipolar I depression: data from 920 patients. ( Davis, KH; Fieve, RR; Harris, SD; Krishnan, AA; Lecrubier, Y; Yatham, LN, 2004) |
| "Lamotrigine was considered to have mixed support." | 2.47 | Pharmacotherapy for the treatment of acute bipolar II depression: current evidence. ( Swartz, HA; Thase, ME, 2011) |
| "Lamotrigine has also demonstrated significant efficacy in recent studies and has been approved by the FDA." | 2.42 | Bipolar depression: an overview. ( Oral, ET; Vahip, S, 2004) |
| "Lamotrigine has emerged as a first line treatment for bipolar depression, which is an area of weakness for other mood stabilizers." | 2.42 | Separate and concomitant use of lamotrigine, lithium, and divalproex in bipolar disorders. ( Goodwin, FK; Lieberman, DZ, 2004) |
| "Valproic acid is an effective anti-epileptic medication often used for long-term control of seizure disorders that has been implicated in hematological toxicities, including rare reports of myelodysplasia and acute leukemia." | 1.35 | Translocation-positive acute myeloid leukemia associated with valproic acid therapy. ( Ben-Ezra, J; Massey, GV; Riley, RS; Russell, EC; Williams, DC, 2008) |
| "For the management of bipolar depression, new data support quetiapine monotherapy as a first-line option." | 1.33 | Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines for the management of patients with bipolar disorder: update 2007. ( Beaulieu, S; Kennedy, SH; MacQueen, G; McIntyre, RS; O'Donovan, C; Parikh, SV; Sharma, V; Yatham, LN, 2006) |
| "Acute interstitial nephritis is a mononuclear and sterile inflammation of the renal interstice caused by drugs, infections or immune phenomena." | 1.32 | [Acute interstitial nephritis associated to lamotrigine use. Report of one case]. ( Mönckeberg, G; Rosenberg, H; Valls, G; Vukusich, A, 2004) |
| "In severe myoclonic epilepsy of infancy (SME), multiple drug-resistant focal and generalized seizure types occur." | 1.30 | Lamotrigine and seizure aggravation in severe myoclonic epilepsy. ( Belmonte, A; Dravet, C; Dulac, O; Genton, P; Guerrini, R; Kaminska, A, 1998) |
| " Seizures became diurnal and frequent, not modified by carbamazepine (CBZ) or valproate (VPA) but responding to VPA and lamotrigine (LTG) with recommended dosage schedules for this combination." | 1.30 | Paradoxic reaction to lamotrigine in a child with benign focal epilepsy of childhood with centrotemporal spikes. ( Boyd, S; Catania, S; Cross, H; de Sousa, C, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 7 (16.67) | 18.2507 |
| 2000's | 25 (59.52) | 29.6817 |
| 2010's | 10 (23.81) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Woodcock, IR | 1 |
| Taylor, LE | 1 |
| Ruddle, JB | 1 |
| Freeman, JL | 1 |
| Dabscheck, G | 1 |
| Sandalon, S | 1 |
| Könnecke, B | 1 |
| Levkovitch-Verbin, H | 1 |
| Simons, M | 1 |
| Hein, K | 1 |
| Sättler, MB | 1 |
| Bähr, M | 1 |
| Ofri, R | 1 |
| Wiffen, PJ | 3 |
| Derry, S | 2 |
| Moore, RA | 2 |
| Ketter, TA | 1 |
| Miller, S | 1 |
| Dell'Osso, B | 1 |
| Calabrese, JR | 3 |
| Frye, MA | 1 |
| Citrome, L | 1 |
| Nwogbe, B | 1 |
| Ferié, J | 1 |
| Smith, H | 1 |
| Gunawardena, I | 1 |
| Dhatariya, K | 1 |
| Swartz, HA | 1 |
| Thase, ME | 1 |
| Sachs, GS | 1 |
| Ice, KS | 1 |
| Chappell, PB | 1 |
| Schwartz, JH | 1 |
| Gurtovaya, O | 1 |
| Vanderburg, DG | 1 |
| Kasuba, B | 1 |
| Waldo, SW | 1 |
| Treit, K | 1 |
| Goldschlager, N | 1 |
| Wittebole, X | 1 |
| Hantson, P | 1 |
| Guerry, MJ | 1 |
| Lemyze, M | 1 |
| Laughlin, TM | 1 |
| Tram, KV | 1 |
| Wilcox, GL | 1 |
| Birnbaum, AK | 1 |
| Grunze, H | 3 |
| Dittmann, S | 1 |
| French, JA | 1 |
| Kanner, AM | 1 |
| Bautista, J | 1 |
| Abou-Khalil, B | 1 |
| Browne, T | 1 |
| Harden, CL | 1 |
| Theodore, WH | 1 |
| Bazil, C | 1 |
| Stern, J | 1 |
| Schachter, SC | 1 |
| Bergen, D | 1 |
| Hirtz, D | 1 |
| Montouris, GD | 1 |
| Nespeca, M | 1 |
| Gidal, B | 1 |
| Marks, WJ | 1 |
| Turk, WR | 1 |
| Fischer, JH | 1 |
| Bourgeois, B | 1 |
| Wilner, A | 1 |
| Faught, RE | 1 |
| Sachdeo, RC | 1 |
| Beydoun, A | 1 |
| Glauser, TA | 1 |
| Hsu, D | 1 |
| Sandborg, C | 1 |
| Hahn, JS | 1 |
| Mönckeberg, G | 1 |
| Vukusich, A | 1 |
| Valls, G | 1 |
| Rosenberg, H | 1 |
| Holzer, L | 1 |
| Halfon, O | 1 |
| Yatham, LN | 2 |
| Lecrubier, Y | 1 |
| Fieve, RR | 1 |
| Davis, KH | 1 |
| Harris, SD | 1 |
| Krishnan, AA | 1 |
| Oral, ET | 1 |
| Vahip, S | 1 |
| Lieb, K | 1 |
| Walden, J | 2 |
| Fiebich, BL | 1 |
| Berger, M | 1 |
| Normann, C | 2 |
| Lieberman, DZ | 1 |
| Goodwin, FK | 1 |
| Muzina, DJ | 1 |
| Elhaj, O | 1 |
| Gajwani, P | 1 |
| Gao, K | 1 |
| Patrizi, A | 1 |
| Savoia, F | 1 |
| Negosanti, F | 1 |
| Posar, A | 1 |
| Santucci, M | 1 |
| Neri, I | 1 |
| Kennedy, SH | 1 |
| O'Donovan, C | 1 |
| Parikh, SV | 1 |
| MacQueen, G | 1 |
| McIntyre, RS | 1 |
| Sharma, V | 1 |
| Beaulieu, S | 1 |
| Genton, P | 2 |
| Gelisse, P | 1 |
| Crespel, A | 1 |
| Williams, DC | 1 |
| Massey, GV | 1 |
| Russell, EC | 1 |
| Riley, RS | 1 |
| Ben-Ezra, J | 1 |
| Rees, J | 1 |
| Konstantakopoulos, G | 1 |
| Oulis, P | 1 |
| Koulouris, GC | 1 |
| Masdrakis, VG | 1 |
| Michalopoulou, PG | 1 |
| Suppes, T | 1 |
| Marangell, LB | 1 |
| Bernstein, IH | 1 |
| Kelly, DI | 1 |
| Fischer, EG | 1 |
| Zboyan, HA | 1 |
| Snow, DE | 1 |
| Martinez, M | 1 |
| Al Jurdi, R | 1 |
| Shivakumar, G | 1 |
| Sureddi, S | 1 |
| Gonzalez, R | 1 |
| Jadresic, D | 1 |
| Nakamura-Craig, M | 1 |
| Follenfant, RL | 1 |
| Hunter, JC | 1 |
| Gogas, KR | 1 |
| Hedley, LR | 1 |
| Jacobson, LO | 1 |
| Kassotakis, L | 1 |
| Thompson, J | 1 |
| Fontana, DJ | 1 |
| Feeney, J | 1 |
| Guerrini, R | 1 |
| Dravet, C | 1 |
| Belmonte, A | 1 |
| Kaminska, A | 1 |
| Dulac, O | 1 |
| Gómez Caturla, A | 1 |
| Arteta Jiménez, M | 1 |
| Fernández Planelles, C | 1 |
| Portillo, J | 1 |
| Catania, S | 1 |
| Cross, H | 1 |
| de Sousa, C | 1 |
| Boyd, S | 1 |
| Ichim, L | 1 |
| Berk, M | 1 |
| Brook, S | 1 |
| Sauvé, G | 1 |
| Bresson-Hadni, S | 1 |
| Prost, P | 1 |
| Le Calvez, S | 1 |
| Becker, MC | 1 |
| Galmiche, J | 1 |
| Carbillet, JP | 1 |
| Miguet, JP | 1 |
| Wensween, CA | 1 |
| Bouwes Bavinck, JN | 1 |
| Shelton, MD | 1 |
| Rapport, DJ | 1 |
| Kujawa, M | 1 |
| Kimmel, SE | 1 |
| Caban, S | 1 |
| Chengappa, KN | 1 |
| Gershon, S | 1 |
| Levine, J | 1 |
| Hummel, B | 1 |
| Schärer, LO | 1 |
| Hörn, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Six-Week, Double-Blind, Multicenter, Placebo Controlled Study Evaluating The Efficacy And Safety Of Flexible Doses Of Oral Ziprasidone As Add-On, Adjunctive Therapy With Lithium, Valproate Or Lamotrigine In Bipolar I Depression[NCT00483548] | Phase 3 | 298 participants (Actual) | Interventional | 2007-10-31 | Completed | ||
| Light-Therapy in the Treatment of the Acute Phase of the Bipolar Type II Depression: Double-Blind, Placebo-Controlled Study to Establish Efficacy and Safety[NCT00590265] | 50 participants (Anticipated) | Interventional | 2008-01-31 | Active, not recruiting | |||
| Acute Treatment of Bipolar II Depression[NCT00074776] | Phase 3 | 102 participants (Actual) | Interventional | 2003-05-31 | Completed | ||
| Comparison of Oral Lamotrigine Versus Pregabalin for Control of Acute and Chronic Pain Following Modified Radical Mastectomy: Controlled Double-blind Study[NCT03419949] | 0 participants | Expanded Access | Available | ||||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
CGI-S is a single-item clinician rated scale used to assess global severity of bipolar illness based on an overall evaluation of symptoms of bipolar mania, associated behavioral symptoms, and condition of the subject. Scored from 1 (normal, not at all ill) to 7 (among the most severely ill subjects). Higher score = more affected. Change calculated as a difference between post-baseline observation and baseline CGI-S score values. (NCT00483548)
Timeframe: Baseline, Week 6
| Intervention | scores on scale (Mean) |
|---|---|
| Ziprasidone | -1.5 |
| Placebo | -1.5 |
MADRS is a 10-item clinician rated scale to measure overall severity of depressive symptoms (apparent sadness, reported sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, suicidal thoughts); rated on a 7-point Likert scale 0 (normal) to 6 (most abnormal); total score 0 to 44 (higher score indicates greater severity of symptoms). Change calculated as a difference between post-baseline observation and baseline MADRS score values. (NCT00483548)
Timeframe: Baseline, Week 6
| Intervention | scores on scale (Mean) |
|---|---|
| Ziprasidone | -14.7 |
| Placebo | -13.2 |
Number of subjects with improvement defined as CGI-I response of 1 (very much improved) or 2 (much improved). CGI-I is a single-item clinician rated scale used to assess global improvement in the subject's clinical state (bipolar mania) in response to study treatment and as compared to their status at pre-treatment baseline. Scores range from 1 (very much improved) to 4 (no change) to 7 (very much worse). Higher score = more affected. (NCT00483548)
Timeframe: Baseline, Week 6
| Intervention | participants (Number) |
|---|---|
| Ziprasidone | 66 |
| Placebo | 69 |
Number of subjects with MADRS total score ≤ 12 (indicates remission). MADRS is a 10-item clinician rated scale to measure overall severity of depressive symptoms (apparent sadness, reported sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, suicidal thoughts); rated on a 7-point Likert scale 0 (normal) to 6 (most abnormal); total score 0 to 44 (higher score indicates greater severity of symptoms). (NCT00483548)
Timeframe: Week 6
| Intervention | participants (Number) |
|---|---|
| Ziprasidone | 48 |
| Placebo | 54 |
Number of subjects with reduction of ≥50 percent (%) in MADRS total score (indicates response). MADRS is a 10-item clinician rated scale to measure overall severity of depressive symptoms (apparent sadness, reported sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, suicidal thoughts); rated on a 7-point Likert scale 0 (normal) to 6 (most abnormal); total score 0 to 44 (higher score indicates greater severity of symptoms). Reduction calculated as ([A-B]/B*100): A=value at observation; B=baseline value. (NCT00483548)
Timeframe: Week 6
| Intervention | participants (Number) |
|---|---|
| Ziprasidone | 62 |
| Placebo | 65 |
CGI-I is a single-item clinician rated scale used to assess global improvement in the subject's clinical state (bipolar mania) in response to study treatment and as compared to their status at pre-treatment baseline. Scores range from 1 (very much improved) to 4 (no change) to 7 (very much worse). Higher score = more affected. Week 6 is the primary timepoint. (NCT00483548)
Timeframe: Week 1, Week 2, Week 3, Week 4, Week 5, Week 6
| Intervention | scores on scale (Mean) | |||||
|---|---|---|---|---|---|---|
| Week 1 (n=142, 141) | Week 2 (n=120, 138) | Week 3 (n=115, 130) | Week 4 (n=106, 122) | Week 5 (n=103, 112) | Week 6 (n=92, 108) | |
| Placebo | 3.4 | 3.1 | 2.9 | 2.8 | 2.6 | 2.4 |
| Ziprasidone | 3.2 | 2.9 | 2.7 | 2.6 | 2.5 | 2.4 |
AIMS is a clinician rated 12-item scale to rate 7 body areas and global judgments on the severity of abnormal movements, incapacitation and subject's awareness of abnormal movements. Items 1 to 10 scored 0 (none) to 4 (severe); items 11 to 14 are No or Yes response to dental status and sleep movements and are assessed separately. AIMS total score is sum of first 7 items. Change calculated as a difference between post-baseline observation and baseline AIMS score values. (NCT00483548)
Timeframe: Baseline, Week 2, Week 4, Week 6
| Intervention | scores on scale (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Total score: Week 2 (n=136, 142) | Total score: Week 4 (n=111, 127) | Total score: Week 6 (n=100, 111) | Global severity score: Week 2 (n=136, 142) | Global severity score: Week 4 (n=111, 127) | Global severity score: Week 6 (n=100, 111) | Incapacitation score: Week 2 (n=136, 142) | Incapacitation score: Week 4 (n=111, 127) | Incapacitation score: Week 6 (n=100, 111) | |
| Placebo | -0.1 | -0.0 | -0.0 | -0.0 | 0.0 | 0.0 | -0.0 | -0.0 | 0.0 |
| Ziprasidone | 0.1 | -0.0 | -0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
BARS is a clinician rated scale to evaluate akathisia associated with use of antipsychotic medications: objective motor restlessness, range 0 to 3; subjective complaints of restlessness and associated distress, range 0 to 3; global clinical assessment of akathisia, range 0 to 5. Higher scores indicate more affected. Change calculated as a difference between post-baseline observation and baseline BARS score values. (NCT00483548)
Timeframe: Baseline, Week 2, Week 4, Week 6
| Intervention | scores on scale (Mean) | ||
|---|---|---|---|
| Week 2 (n=135, 139) | Week 4 (n=111, 125) | Week 6 (n=100, 110) | |
| Placebo | -0.0 | 0.0 | -0.0 |
| Ziprasidone | 0.1 | 0.0 | 0.0 |
CGI-S is a single-item clinician rated scale used to assess global severity of bipolar illness based on an overall evaluation of symptoms of bipolar mania, associated behavioral symptoms, and condition of the subject. Scores range from 1 (normal, not at all ill) to 7 (among the most severely ill subjects). Higher score = more affected. Change calculated as a difference between post-baseline observation and baseline CGI-S score values. (NCT00483548)
Timeframe: Baseline, Week 1, Week 2, Week 3, Week 4, Week 5
| Intervention | scores on scale (Mean) | ||||
|---|---|---|---|---|---|
| Week 1 (n=142, 141) | Week 2 (n=120, 139) | Week 3 (n=115, 130) | Week 4 (n=106, 122) | Week 5 (n=103, 112) | |
| Placebo | -0.4 | -0.7 | -0.9 | -1.1 | -1.3 |
| Ziprasidone | -0.5 | -0.9 | -0.9 | -1.1 | -1.3 |
GAF is a clinician rated scale to measure the severity of illness-related impairment in psychological, social, and occupational functioning using a 100-point scale (single score of 1 to 100) with 100 indicating a superior level of function. Change calculated as a difference between post-baseline observation and baseline GAF score values. (NCT00483548)
Timeframe: Baseline, Week 6
| Intervention | scores on scale (Mean) | |
|---|---|---|
| Week 6 (n=100, 110) | ET (n=34, 27) | |
| Placebo | 11.2 | 2.8 |
| Ziprasidone | 14.7 | 0.0 |
HAM-A is a clinician rated 14-item scale that rates the intensity of psychic anxiety (items 1 to 6 and item 14) and somatic anxiety (items 7 to 13) on a 5-point severity scale; scores range from 0 (not present) to 4 (very severe); lower score indicates less affected. Change calculated as a difference between post-baseline observation and baseline HAM-A score values. Week 6 is the primary timepoint. (NCT00483548)
Timeframe: Baseline, Week 2, Week 4, Week 6
| Intervention | scores on scale (Mean) | ||
|---|---|---|---|
| Week 2 (n=136, 141) | Week 4 (n=111, 127) | Week 6 (n=100, 111) | |
| Placebo | -5.9 | -7.4 | -8.6 |
| Ziprasidone | -5.6 | -7.1 | -8.5 |
MADRS is a 10-item clinician rated scale to measure overall severity of depressive symptoms (apparent sadness, reported sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, suicidal thoughts); rated on a 7-point Likert scale 0 (normal) to 6 (most abnormal); total score 0 to 44 (higher score indicates greater severity of symptoms). Change calculated as a difference between post-baseline observation and baseline MADRS score values. (NCT00483548)
Timeframe: Baseline, Week 1, Week 2, Week 3, Week 4, Week 5
| Intervention | scores on scale (Mean) | ||||
|---|---|---|---|---|---|
| Week 1 (n=142, 141) | Week 2 (n=121, 139) | Week 3 (n=115, 130) | Week 4 (n=106, 122) | Week 5 (n=103, 112) | |
| Placebo | -6.1 | -9.0 | -11.0 | -11.8 | -13.3 |
| Ziprasidone | -8.1 | -11.7 | -13.0 | -14.1 | -14.9 |
Q-LES-Q is a 16-item subject rated scale to measure satisfaction with areas of daily functioning (physical health, social relationships, medication, and overall life satisfaction); rated on a 5-point Likert scale: higher scores indicate greater enjoyment and satisfaction with general life activities. Scores for items 1 to 14 are summed for a total score and converted to 0 to 100 range. Items 15 and 16 measure satisfaction with medication and overall satisfaction and are analyzed separately. Change calculated as a difference between post-baseline observation and baseline Q-LES-Q score values. (NCT00483548)
Timeframe: Baseline, Week 6
| Intervention | scores on scale (Mean) | |||||
|---|---|---|---|---|---|---|
| Total Q-LES-Q: Week 6 (n=82, 94) | Total Q-LES-Q: ET (n=27, 17) | Medications: Week 6 (n=91, 93) | Medications: ET (n=27, 20) | Overall life satisfaction: Week 6 (n=94, 103) | Overall life satisfaction: ET (n=31, 23) | |
| Placebo | 11.6 | 1.6 | 0.3 | -0.4 | 0.5 | 0.0 |
| Ziprasidone | 15.2 | -0.1 | 0.4 | -0.3 | 0.8 | 0.1 |
SDS is a 5-item subject rated scale to measure the extent to which work and or school, social life and or leisure activities, and home life and or family responsibilities were impaired by psychiatric illness. Items 1 to 3 rated on 11-point scale ranging 0 (not at all) to 10 (extremely affected). Total score 0 to 30; higher score indicates greater impairment; items 4 and 5 report number of days in the last month (0 to 31) subject missed work or school or was unproductive and are rated separately. Change calculated as a difference between post-baseline observation and baseline SDS score values. (NCT00483548)
Timeframe: Baseline, Week 6
| Intervention | scores on scale (Mean) | |||||||
|---|---|---|---|---|---|---|---|---|
| Total SDS: Week 6 (n=58, 63) | Total SDS: ET (n=19, 14) | Work/School: Week 6 (n=58, 64) | Work/School: ET (n=19, 14) | Social life: Week 6 (n=94, 102) | Social life: ET (n=31, 23) | Family/Home: Week 6 (n=94, 102) | Family/Home: ET (n=31, 23) | |
| Placebo | -3.7 | -1.4 | -1.6 | -0.1 | -1.7 | 0.1 | -1.7 | -0.6 |
| Ziprasidone | -8.5 | 0.2 | -2.1 | 0.4 | -2.5 | -0.5 | -2.6 | 0.2 |
SDS is a 5-item subject rated scale to measure the extent to which work and or school, social life and or leisure activities, and home life and or family responsibilities were impaired by psychiatric illness. Items 1 to 3 rated on 11-point scale ranging 0 (not at all) to 10 (extremely affected). Total score 0 to 30; higher score indicates greater impairment; items 4 and 5 report number of days in the last month (0 to 31) subject missed work or school or was unproductive and are rated separately. Change calculated as a difference between post-baseline observation and baseline SDS score values. (NCT00483548)
Timeframe: Baseline, Week 6
| Intervention | days (Mean) | |||
|---|---|---|---|---|
| Days lost: Week 6 (n=85, 93) | Days lost: ET (n=29, 21) | Days unproductive: Week 6 (n=87, 89) | Days unproductive: ET (n=29, 21) | |
| Placebo | -0.7 | 0.0 | -1.3 | -0.1 |
| Ziprasidone | -1.2 | 0.5 | -1.6 | -0.2 |
SAS is a clinician rated 10-item scale to measure extrapyramidal side effects (Parkinsonism or Parkinsonian side effects induced with antipsychotics); rated on a 5-point scale with range 0 (absence of condition) to 4 (presence of condition in extreme form). Global score is sum of all scores divided by the total number of items. Change calculated as a difference between post-baseline observation and baseline SAS score values. (NCT00483548)
Timeframe: Baseline, Week 2, Week 4, Week 6
| Intervention | scores on scale (Mean) | ||
|---|---|---|---|
| Week 2 (n=136, 141) | Week 4 (n=111, 126) | Week 6 (n=100, 110) | |
| Placebo | -0.1 | 0.0 | -0.1 |
| Ziprasidone | 0.1 | 0.0 | 0.0 |
YMRS is clinician rated 11-item scale (elevated mood, increased motor activity-energy, sexual interest, sleep, irritability, speech [rate and amount], language-thought disorder, content, disruptive-aggressive behavior, appearance, and insight) used to assess the severity of manic symptoms and effect of treatment on mania severity. Seven items ranked on scale from 0 to 4; 4 items ranked 0 to 8. Higher scores indicate greater severity. Change calculated as a difference between post-baseline observation and baseline YMRS score values. Week 6 is the primary timepoint. (NCT00483548)
Timeframe: Baseline, Week 1, Week 2, Week 3, Week 4, Week 5, Week 6
| Intervention | scores on scale (Mean) | |||||
|---|---|---|---|---|---|---|
| Week 1 (n=142, 141) | Week 2 (n=121, 139) | Week 3 (n=115, 130) | Week 4 (n=106, 122) | Week 5 (n=103, 112) | Week 6 (n=92, 108) | |
| Placebo | -0.2 | -0.2 | -0.2 | -1.1 | -1.3 | -0.9 |
| Ziprasidone | 0.7 | 0.5 | -0.0 | -0.9 | -0.9 | -1.0 |
13 reviews available for lamotrigine and Acute Disease
| Article | Year |
|---|---|
Lamotrigine for chronic neuropathic pain and fibromyalgia in adults.
Topics: Acute Disease; Adult; Analgesics; Anticonvulsants; Chronic Disease; Fibromyalgia; Humans; Lamotrigin | 2013 |
Balancing benefits and harms of treatments for acute bipolar depression.
Topics: Acute Disease; Antidepressive Agents; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Diben | 2014 |
Pharmacotherapy for the treatment of acute bipolar II depression: current evidence.
Topics: Acute Disease; Antidepressive Agents; Antimanic Agents; Benzhydryl Compounds; Benzothiazoles; Bipola | 2011 |
Lamotrigine for acute and chronic pain.
Topics: Acute Disease; Analgesics; Chronic Disease; Humans; Lamotrigine; Pain; Randomized Controlled Trials | 2011 |
Use of the molecular adsorbent recirculating system (MARS™) for the management of acute poisoning with or without liver failure.
Topics: Acetaminophen; Acute Disease; Albumins; Amanita; Amphetamine; Calcium Channel Blockers; Cocaine; Hea | 2011 |
[Treatment of acute bipolar disorder. Intriguing balancing act between mania and depression].
Topics: Acute Disease; Algorithms; Antidepressive Agents; Antimanic Agents; Antipsychotic Agents; Benzodiaze | 2003 |
Efficacy and tolerability of the new antiepileptic drugs I: treatment of new onset epilepsy: report of the Therapeutics and Technology Assessment Subcommittee and Quality Standards Subcommittee of the American Academy of Neurology and the American Epileps
Topics: Acetates; Acute Disease; Adolescent; Adult; Amines; Anticonvulsants; Carbamazepine; Child; Controlle | 2004 |
Bipolar depression: an overview.
Topics: Acute Disease; Antidepressive Agents; Antimanic Agents; Benzodiazepines; Bipolar Disorder; Chemoprev | 2004 |
Separate and concomitant use of lamotrigine, lithium, and divalproex in bipolar disorders.
Topics: Acute Disease; Administration, Oral; Antimanic Agents; Bipolar Disorder; Drug Therapy, Combination; | 2004 |
Lamotrigine and antiepileptic drugs as mood stabilizers in bipolar disorder.
Topics: Acute Disease; Amines; Anticonvulsants; Antimanic Agents; Bipolar Disorder; Carbamazepine; Cyclohexa | 2005 |
Lamotrigine for acute and chronic pain.
Topics: Acute Disease; Analgesics; Anticonvulsants; Chronic Disease; Humans; Lamotrigine; Pain; Randomized C | 2007 |
Current research on rapid cycling bipolar disorder and its treatment.
Topics: Acute Disease; Antimanic Agents; Bipolar Disorder; Carbamazepine; Drug Administration Schedule; Drug | 2001 |
The evolving role of topiramate among other mood stabilizers in the management of bipolar disorder.
Topics: Acetates; Acute Disease; Amines; Anticonvulsants; Antimanic Agents; Bipolar Disorder; Carbamazepine; | 2001 |
8 trials available for lamotrigine and Acute Disease
| Article | Year |
|---|---|
Efficacy and safety of adjunctive oral ziprasidone for acute treatment of depression in patients with bipolar I disorder: a randomized, double-blind, placebo-controlled trial.
Topics: Acute Disease; Adolescent; Adult; Aged; Antimanic Agents; Bipolar Disorder; Depressive Disorder, Maj | 2011 |
Quality of life in patients with bipolar I depression: data from 920 patients.
Topics: Acute Disease; Adult; Antipsychotic Agents; Bipolar Disorder; Depressive Disorder; Double-Blind Meth | 2004 |
Serum levels of substance P and response to antidepressant pharmacotherapy.
Topics: Acute Disease; Adult; Antidepressive Agents; Depressive Disorder, Major; Humans; Lamotrigine; Paroxe | 2004 |
Lack of efficacy and potential aggravation of myoclonus with lamotrigine in Unverricht-Lundborg disease.
Topics: Acute Disease; Adult; Age of Onset; Anticonvulsants; Dose-Response Relationship, Drug; Drug Therapy, | 2006 |
A single blind comparison of lithium and lamotrigine for the treatment of bipolar II depression.
Topics: Acute Disease; Adolescent; Adult; Aged; Ambulatory Care; Anticonvulsants; Bipolar Disorder; Diagnost | 2008 |
Lamotrigine compared with lithium in mania: a double-blind randomized controlled trial.
Topics: Acute Disease; Adolescent; Adult; Antimanic Agents; Bipolar Disorder; Double-Blind Method; Female; H | 2000 |
The evolving role of topiramate among other mood stabilizers in the management of bipolar disorder.
Topics: Acetates; Acute Disease; Amines; Anticonvulsants; Antimanic Agents; Bipolar Disorder; Carbamazepine; | 2001 |
Lamotrigine as adjunct to paroxetine in acute depression: a placebo-controlled, double-blind study.
Topics: Acute Disease; Adolescent; Adult; Aged; Anticonvulsants; Depressive Disorder; Double-Blind Method; D | 2002 |
22 other studies available for lamotrigine and Acute Disease
| Article | Year |
|---|---|
Acute bilateral myopia caused by lamotrigine-induced uveal effusions.
Topics: Acute Disease; Adolescent; Anticonvulsants; Female; Humans; Lamotrigine; Myopia; Treatment Outcome; | 2017 |
Functional and structural evaluation of lamotrigine treatment in rat models of acute and chronic ocular hypertension.
Topics: Acute Disease; Administration, Topical; Animals; Axons; Chronic Disease; Disease Models, Animal; Ele | 2013 |
Significant lamotrigine overdose associated with acute pancreatitis.
Topics: Acute Disease; Antidepressive Agents; Drug Overdose; Female; Humans; Lamotrigine; Pancreatitis; Tria | 2009 |
Possible acute myocardial infarction in a hypothermic patient.
Topics: Acute Disease; Anticonvulsants; Antimanic Agents; Benzodiazepines; Bipolar Disorder; Drug Overdose; | 2011 |
Acute skin failure.
Topics: Acute Disease; Amoxicillin; Anti-Bacterial Agents; Anticonvulsants; Biopsy; Diagnosis, Differential; | 2012 |
Comparison of antiepileptic drugs tiagabine, lamotrigine, and gabapentin in mouse models of acute, prolonged, and chronic nociception.
Topics: Acetates; Acute Disease; Adrenergic alpha-Agonists; Amines; Analgesics, Non-Narcotic; Analgesics, Op | 2002 |
Frontal lobe seizures and uveitis associated with acute human parvovirus B19 infection.
Topics: Acute Disease; Anti-Inflammatory Agents; Anticonvulsants; Brain; Carbamazepine; Child, Preschool; El | 2004 |
[Acute interstitial nephritis associated to lamotrigine use. Report of one case].
Topics: Acute Disease; Adult; Antidepressive Agents; Granuloma; Humans; Kidney; Lamotrigine; Male; Nephritis | 2004 |
Normalization of impaired cognitive functions failed to improve clinical symptomatology in a schizophrenic patient.
Topics: Acute Disease; Adolescent; Antipsychotic Agents; Benzodiazepines; Brain; Cognition Disorders; Electr | 2004 |
Telogen effluvium caused by magnesium valproate and lamotrigine.
Topics: Acute Disease; Adolescent; Adult; Alopecia; Anticonvulsants; Epilepsy; Female; Humans; Lamotrigine; | 2005 |
Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines for the management of patients with bipolar disorder: update 2007.
Topics: Acute Disease; Antidepressive Agents; Antipsychotic Agents; Anxiety Disorders; Benzodiazepines; Bipo | 2006 |
Translocation-positive acute myeloid leukemia associated with valproic acid therapy.
Topics: Acute Disease; Anticonvulsants; Cell Differentiation; Cell Division; Child, Preschool; Chromosomes, | 2008 |
Lamotrigine-associated exacerbation of positive symptoms in paranoid schizophrenia.
Topics: Acute Disease; Adult; Anticonvulsants; Diagnostic and Statistical Manual of Mental Disorders; Humans | 2008 |
Acute pancreatitis associated with dual vigabatrin and lamotrigine therapy.
Topics: Acute Disease; Adult; Amylases; Anticonvulsants; Epilepsy, Complex Partial; gamma-Aminobutyric Acid; | 1994 |
Effect of lamotrigine in the acute and chronic hyperalgesia induced by PGE2 and in the chronic hyperalgesia in rats with streptozotocin-induced diabetes.
Topics: Acute Disease; Analgesics; Animals; Anticonvulsants; Chronic Disease; Diabetes Mellitus, Experimenta | 1995 |
The effect of novel anti-epileptic drugs in rat experimental models of acute and chronic pain.
Topics: Acetates; Acute Disease; Amines; Analgesics; Animals; Anticonvulsants; Chronic Disease; Cyclohexanec | 1997 |
Diaminopyrimidines and severe cutaneous adverse reactions.
Topics: Acute Disease; Anticonvulsants; Antimalarials; Drug Eruptions; Humans; Lamotrigine; Pyrimethamine; P | 1997 |
Lamotrigine and seizure aggravation in severe myoclonic epilepsy.
Topics: Acute Disease; Adolescent; Adult; Anticonvulsants; Child; Comorbidity; Drug Therapy, Combination; Ep | 1998 |
[Acute hepatitis associated with lamotrigine administration].
Topics: Acute Disease; Adult; Anticonvulsants; Chemical and Drug Induced Liver Injury; Humans; Lamotrigine; | 1998 |
Paradoxic reaction to lamotrigine in a child with benign focal epilepsy of childhood with centrotemporal spikes.
Topics: Acute Disease; Anticonvulsants; Carbamazepine; Child; Electroencephalography; Epilepsy, Absence; Epi | 1999 |
Acute hepatitis after lamotrigine administration.
Topics: Acute Disease; Adult; Anticonvulsants; Chemical and Drug Induced Liver Injury; Disseminated Intravas | 2000 |
[Overlapping acute disseminated exanthematous pustulosis and toxic epidermal necrolysis].
Topics: Acute Disease; Adult; Anticonvulsants; Diagnosis, Differential; Exanthema; Female; Fever; Humans; La | 2001 |